-
Electronic (PDF)
-
Site License
-
Enterprisewide
Neuralgia - Pipeline Review, Q2 2011
Global Markets Direct, May 2011, Pages: 340
Neuralgia - Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, 'Neuralgia - Pipeline Review, Q2 2011', provides an overview of the Neuralgia therapeutic pipeline. This report provides information on the therapeutic development for Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuralgia. 'Neuralgia - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neuralgia.
- A review of the Neuralgia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuralgia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuralgia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuralgia pipeline depth and focus of Neuralgia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuralgia Overview
Therapeutics Development
An Overview of Pipeline Products for Neuralgia
Neuralgia Therapeutics under Development by Companies
Neuralgia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Neuralgia Therapeutics - Products under Development by Companies
Neuralgia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Neuralgia Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Biogen Idec Inc.
Allergan, Inc.
NsGene A/S
Valeant Pharmaceuticals International
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
BioDelivery Sciences International, Inc.
GlaxoSmithKline plc
Nektar Therapeutics
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Sangamo BioSciences, Inc.
ZARS Pharma, Inc.
XenoPort, Inc.
BioLineRx, Ltd.
Daewoong Pharmaceutical Co., Ltd.
Depomed, Inc.
Eisai Co., Ltd.
Gedeon Richter Plc.
Glenmark Pharmaceuticals Ltd.
Japan Tobacco Inc.
Pfizer Inc.
Vernalis plc
EpiCept Corporation
Evotec Aktiengesellschaft
GW Pharmaceuticals plc
Anavex Life Sciences Corp.
AVANIR Pharmaceuticals
Lpath, Inc.
MediciNova, Inc.
Medivir AB
NeuroDiscovery Ltd
NeurogesX, Inc.
NicOx SA
NPS Pharmaceuticals, Inc.
Pharmos Corporation
Adolor Corp.
CombinatoRx, Incorporated
Torrent Pharmaceuticals Limited
Diamyd Medical AB
SCOLR Pharma, Inc.
Pluristem Therapeutics Inc.
DARA BioSciences, Inc.
Proximagen Neuroscience plc.
Newron Pharmaceuticals S.p.A.
Raptor Pharmaceuticals Corp.
Angelini Group
Ajanta Pharma Limited
Auspex Pharmaceuticals
VistaGen Therapeutics , Inc.
Bionorica AG
Snowdon Inc.
Neurotune AG
Grunenthal GmbH
Xenon Pharmaceuticals Inc.
CREABILIS Therapeutics S.r.l.
Amura Holdings Ltd.
Affectis Pharmaceuticals AG
BioQuest Innovations Inc.
Grupo Uriach
Chlorion Pharma, Inc.
Rottapharm SpA
WEX Pharmaceuticals Inc.
Hydra Biosciences, Inc.
Yaupon Therapeutics, Inc.
NeurAxon, Inc.
Virobay Inc.
QRxPharma Limited
Cara Therapeutics, Inc.
Kalypsys, Inc.
Bial Group
Xenome Ltd.
Krenitsky Pharmaceuticals Inc.
Lectus Therapeutics Limited
KAI Pharmaceuticals Inc.
Winston Pharmaceuticals, Inc.
Bial - Portela & Ca, S.A.
UCB S.A.
TheraQuest Biosciences, LLC
Celtic Pharmaceutical Holdings L.P.
RaQualia Pharma Inc.
SK Bio-Pharmaceuticals
BUNKER INDUSTRIA FARMACEUTICA LTDA.
Neuralgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Erlosamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UCB 34714 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neublastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR407899 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PH-797804 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lyrica - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Serada - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retigabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SEP-227900 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2516 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2423 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Horizant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVP-923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EVT 101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P2X3 and P2X2/3 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Axomadol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B1 Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NKTR-171 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADL5859 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiprodil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD1940 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-254 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NPSP156 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSC 700 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SND-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IDEA-077 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-11624 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cathespin S Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flexicaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NTDDS NG2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWJ207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-1021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR 4056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMDAR Blocker - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stedesa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UR-13870 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CT327 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carisbamate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levetiracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB681323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ELADUR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRN5500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MN-166 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX-1998 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epicept NP-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEMA Buprenorphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGX426 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZFP TF for Parkinson's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRS-639,058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NXN-462 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSL-043 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bicifadine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tectin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZFP TF For Neuropathic Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-036 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-891 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AVXL 10-90 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MoxDuo CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topical XEN402 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HC-030031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YT-1006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHE377 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neuroprotection And Neural Regeneration Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCR2 Antagonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC 6211 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTS-653 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V158866 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR845 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neurotropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HF 0299 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SKL11197 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ziconotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ralfinamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxycodone + Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AV-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AV-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD7040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sofinicline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Civamide Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gamma Protein kinase C Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cav2.2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KAI-1678 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLP-290 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EHT/AGN 0001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dextromethorphan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avinza - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flecainide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cathepsin S Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00203066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Neuropathic Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP 3089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Civamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42160443 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCR2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TrkA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KP544 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG-33 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG39 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Marijuana - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tramadol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Marijuana - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketorolac + Morphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xen2174 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lamictal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lidocaine Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitatonus Dexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Losmapimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRT3983Y - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin + Duloxetine + Diphenhydramine Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline + Ketamine + Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX 1236 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC 15300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sativex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Etoricoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AGN-214868 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine + Clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin + PF-00489791 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin + Donepezil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin + Venlafaxine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paxil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gamunex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GRC 10693 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Duloxetine + Methadone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin + Eslicarbazepine Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Plasmid VEGF Gene Transfer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANAVEX 1007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-3840 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MCP-1/CCL2 + Selected CytoKines Productions Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFC-5128 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intravenous immunoglobulin + Normal Saline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adenosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cesamet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRPM8 Blocker Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nav 1.7 Blocker Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-Ca (Cav3.2) Blocker Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline + Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR114137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE 3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AF3473 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KHK6188 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNSB015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNSB007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNSB002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TQ-1021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Z212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-954561 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Versatis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATx08-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNS020QD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epikeia + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epikeia + Lidocaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T270 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABT-639 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX For Neuropathic Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neuralgia Therapeutics – Drug Profile Updates
Neuralgia Therapeutics - Discontinued Products
Neuralgia - Featured News
May 02, 2011: Concert Pharmaceuticals Presents Preclinical Data On C-10068 At Antiepileptic Drug Trials XI Conference
May 02, 2011: Xenon’s XEN402 Ointment Significantly Relieves Pain In Patients With Post Herpetic Neuralgia
Apr 28, 2011: NeurogesX Receives Notice Of Allowance For Patent Covering NGX-1998 Capsaicin Topical Liquid
Apr 04, 2011: Avanir Announces Filing Of IND For AVP-923 For Treatment Of Central Neuropathic Pain In Patients With Multiple Sclerosis
Mar 29, 2011: DARA Reports Promising Findings From Phase II Study Of KRN5500 at ADEPT
Mar 09, 2011: MediciNova Receives Notice Of Allowance For Method Of Treating Drug Addiction
Mar 02, 2011: Syntaxin's Partner Allergan Initiates Two Phase II Trials With Re-Targeted Endopeptidase Drug
Feb 25, 2011: Zalicus Publishes Data On Sodium Channel Compound In Pain Models
Feb 09, 2011: NeurogesX To Provide Qutenza Launch Update
Feb 09, 2011: NeurogesX To Provide Qutenza Launch Update
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Neuralgia, Q2 2011
Products under Development for Neuralgia – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Biogen Idec Inc., 2011
Allergan, Inc., 2011
NsGene A/S, 2011
Valeant Pharmaceuticals International, 2011
Amgen Inc., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
BioDelivery Sciences International, Inc., 2011
GlaxoSmithKline plc, 2011
Nektar Therapeutics, 2011
Quark Pharmaceuticals, Inc., 2011
Merck & Co., Inc., 2011
Dainippon Sumitomo Pharma Co., Ltd., 2011
Sangamo BioSciences, Inc., 2011
ZARS Pharma, Inc., 2011
XenoPort, Inc., 2011
BioLineRx, Ltd., 2011
Daewoong Pharmaceutical Co., Ltd., 2011
Depomed, Inc., 2011
Eisai Co., Ltd., 2011
Gedeon Richter Plc., 2011
Glenmark Pharmaceuticals Ltd., 2011
Japan Tobacco Inc., 2011
Pfizer Inc., 2011
Vernalis plc, 2011
EpiCept Corporation, 2011
Evotec Aktiengesellschaft, 2011
GW Pharmaceuticals plc, 2011
Anavex Life Sciences Corp., 2011
AVANIR Pharmaceuticals, 2011
Lpath, Inc., 2011
MediciNova, Inc., 2011
Medivir AB, 2011
NeuroDiscovery Ltd, 2011
NeurogesX, Inc., 2011
NicOx SA, 2011
NPS Pharmaceuticals, Inc., 2011
Pharmos Corporation, 2011
Adolor Corp., 2011
CombinatoRx, Incorporated, 2011
Torrent Pharmaceuticals Limited, 2011
Diamyd Medical AB, 2011
SCOLR Pharma, Inc., 2011
Pluristem Therapeutics Inc., 2011
DARA BioSciences, Inc., 2011
Proximagen Neuroscience plc., 2011
Newron Pharmaceuticals S.p.A., 2011
Raptor Pharmaceuticals Corp., 2011
Angelini Group, 2011
Ajanta Pharma Limited, 2011
Auspex Pharmaceuticals, 2011
VistaGen Therapeutics , Inc., 2011
Bionorica AG, 2011
Snowdon Inc., 2011
Neurotune AG, 2011
Grunenthal GmbH, 2011
Xenon Pharmaceuticals Inc., 2011
CREABILIS Therapeutics S.r.l., 2011
Amura Holdings Ltd., 2011
Affectis Pharmaceuticals AG, 2011
BioQuest Innovations Inc., 2011
Grupo Uriach, 2011
Chlorion Pharma, Inc., 2011
Rottapharm SpA, 2011
WEX Pharmaceuticals Inc., 2011
Hydra Biosciences, Inc., 2011
Yaupon Therapeutics, Inc., 2011
NeurAxon, Inc., 2011
Virobay Inc., 2011
QRxPharma Limited, 2011
Cara Therapeutics, Inc., 2011
Kalypsys, Inc., 2011
Bial Group, 2011
Xenome Ltd., 2011
Krenitsky Pharmaceuticals Inc., 2011
Lectus Therapeutics Limited, 2011
KAI Pharmaceuticals Inc., 2011
Winston Pharmaceuticals, Inc., 2011
Bial - Portela & Ca, S.A., 2011
UCB S.A., 2011
TheraQuest Biosciences, LLC, 2011
Celtic Pharmaceutical Holdings L.P., 2011
RaQualia Pharma Inc., 2011
SK Bio-Pharmaceuticals, 2011
BUNKER INDUSTRIA FARMACEUTICA LTDA., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Neuralgia Therapeutics – Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Neuralgia, Q2 2011
Products under Development for Neuralgia – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
